Investing
Nabi Biopharmaceuticals (NABI) and Third Point LLC Reach Agreement
Published:
From 13D TrackerYesterday morning, Nabi Biopharmaceuticals (Nasdaq: NABI) and dissident shareholder Third Point LLC announced that they have reached a settlement relating to a potential consent solicitation.Under the deal, Nabi Biopharmaceuticals has appointed two Third Point nominees, Jason Aryeh, founder and general partner of JALAA Equities, LP and Tim Lynch, president and CEO of NeuroStat Pharmaceuticals, Inc., to the company’s board of directors. In addition, Nabi Biopharmaceuticals will establish a strategic action committee to continue the company’s previously announced process of exploring strategic alternatives. The Third Point nominees’ will sit on the five member committee.As part of the settlement, Nabi Biopharmaceuticals has agreed to pay up to $250,000 of Third Point’s expenses and Third Point has agreed that it will not commence a consent solicitation or a proxy contest prior to the company’s 2007 annual meeting of shareholders.Third Point CEO, Daniel S. Loeb, said, “We are pleased to be able to work constructively with Nabi Biopharmaceuticals with the shared goal of enhancing the value of the company.”http://www.13dtracker.blogspot.com/
It’s hard to believe, but today there are credit cards offering up to 6% cash back (you read that right) on some items, $200 statement credits, $0 annual fees, travel rewards, and more. See for yourself, we’ve assembled a list of the top credit cards today right here.
Frankly, with rewards this good we don’t expect them to be available forever. But if you sign up today you can secure some of the best rewards we’ve ever seen. Click here to get started.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.